Hospital
Madison Parish Hospital Service District
Madison Parish Hospital Service District was paid $8.80M by Medicaid between Jan 2018 and Dec 2024, across 94 billing codes. Its largest line is 99284, emergency room visit (serious) — 33% of everything it billed.
33Billing provider infoMADISON PARISH HOSPITAL SERVICE DISTRICT
TALLULAH, LA 71282
TALLULAH, LA 71282
33aNPI1851393409assigned 08/12/2005
33bProvider typeCritical Access Hospital
28Total paid$8.80M
24GClaims155,780
24DCodes billed94
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in Louisiana
Rank by total paid#7 of 40
Median peer was paid$3.19M
This provider vs. median2.8×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 17,418 | $993K | |
| 2019 | 23,815 | $1.02M | |
| 2020 | 26,708 | $1.08M | |
| 2021 | 24,961 | $1.60M | |
| 2022 | 26,177 | $1.82M | |
| 2023 | 21,445 | $1.35M | |
| 2024incomplete | 15,256 | $926K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 33% | 11,899 | 10,135 | $2.89M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 16% | 7,355 | 6,354 | $1.44M |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 15% | 3,480 | 3,024 | $1.28M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 8.6% | 2,830 | 2,433 | $761K |
| 71046 | Radiologic examination, chest; 2 views | 5.9% | 5,764 | 4,988 | $519K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 4.1% | 4,962 | 4,282 | $359K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 3.4% | 7,731 | 6,445 | $302K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 2.7% | 5,332 | 4,211 | $238K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.8% | 2,052 | 1,738 | $157K |
| 80053 | Comprehensive metabolic panel | 1.2% | 12,301 | 10,563 | $101K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 1.0% | 3,794 | 3,095 | $90K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 8,661 | 7,613 | $52K |
82 more codes
| 36415 | Collection of venous blood by venipuncture | <1% | 19,247 | $46K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 262 | $39K |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 534 | $39K |
| 74019 | <1% | 216 | $37K | |
| 71045 | Radiologic examination, chest; single view | <1% | 565 | $36K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 290 | $35K |
| 74018 | <1% | 342 | $30K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 58 | $23K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 690 | $23K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 678 | $22K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 651 | $21K |
| 85027 | <1% | 2,919 | $16K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,009 | $14K |
| 80061 | Lipid panel | <1% | 1,400 | $14K |
| 81001 | <1% | 4,058 | $11K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 248 | $10K |
| 86769 | <1% | 187 | $9K | |
| 87581 | <1% | 286 | $9K | |
| 87486 | <1% | 284 | $9K | |
| 84439 | <1% | 1,020 | $8K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 327 | $8K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 105 | $8K |
| J3490 | Unclassified drugs | <1% | 1,761 | $8K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 346 | $7K |
| 84703 | <1% | 928 | $7K | |
| 84484 | <1% | 1,091 | $7K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 277 | $7K |
| 86696 | <1% | 331 | $6K | |
| 87634 | <1% | 88 | $6K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 291 | $6K |
| 83874 | <1% | 848 | $6K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 51 | $5K |
| 82553 | <1% | 746 | $4K | |
| 81003 | <1% | 2,103 | $4K | |
| 86677 | <1% | 302 | $4K | |
| 83880 | <1% | 254 | $4K | |
| 86695 | <1% | 330 | $4K | |
| 85007 | <1% | 1,220 | $4K | |
| 83735 | <1% | 866 | $4K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 545 | $3K |
| 86694 | <1% | 238 | $3K | |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 17,602 | $3K |
| 82550 | <1% | 833 | $3K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 77 | $3K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 192 | $2K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 283 | $2K |
| 81025 | <1% | 311 | $2K | |
| 70220 | <1% | 15 | $2K | |
| 83721 | <1% | 906 | $2K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 305 | $2K |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 235 | $2K |
| 74022 | <1% | 18 | $2K | |
| 86592 | <1% | 381 | $1K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 197 | $1K |
| 82607 | <1% | 77 | $980.20 | |
| 80305 | <1% | 116 | $968.01 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 73 | $910.12 |
| 83605 | <1% | 119 | $746.92 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 78 | $728.00 |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 65 | $484.00 |
| J7510 | Prednisolone oral, per 5 mg | <1% | 82 | $461.65 |
| 84480 | <1% | 56 | $445.23 | |
| 82746 | <1% | 34 | $411.60 | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 55 | $411.57 |
| 82728 | <1% | 33 | $368.01 | |
| 85730 | <1% | 118 | $330.59 | |
| 87807 | <1% | 19 | $305.22 | |
| 83690 | <1% | 73 | $289.86 | |
| 87070 | <1% | 32 | $287.03 | |
| 85610 | <1% | 128 | $251.54 | |
| 87899 | <1% | 17 | $244.55 | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 7,034 | $242.76 |
| 83550 | <1% | 33 | $235.98 | |
| 83540 | <1% | 34 | $181.16 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 57 | $128.30 |
| 85045 | <1% | 33 | $107.73 | |
| 82248 | <1% | 21 | $85.14 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 36 | $73.83 |
| 85379 | <1% | 14 | $71.26 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 15 | $58.40 |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 24 | $46.92 |
| 90853 | Group psychotherapy (other than of a multiple-family group) | 0% | 1,796 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialPERRY, SATIRA (INTERIM CEO)
| Provider | Location | Paid |
|---|---|---|
| Madison Parish Hospital Service District | Tallulah, LA | $12.93M |
| Madison Parish Hospital Service District | Tallulah, LA | $340K |
| Madison Parish Hospital Service District | Tallulah, LA | $383.02 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.